Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
![Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024](report_image/Immuno-OncologyMarketGlobalForecastto2024.jpg)
Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Oct, 2020| No. of Pages : 195
Please make your selection :
Electronic Access - Single User License
US$ 3000.00
CD-ROM Mail Delivery
US$ 3500.00
Hard Copy Mail Delivery
US$ 3500.00
Electronic Access - Multi-User License
US$ 6000.00
List of Figures:
Figure 4-1: Global - Cancer Incidences (Million), 2020, 2025, 2030, 2035 & 2040
Figure 4-2: Global - Cancer Mortality (Million) 2020, 2025, 2030, 2035 & 2040
Figure 4-3: Global - Population above 65 Years (Billion), 2019 & 2050
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2019
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2024
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2018-2024
Figure 6-4: Global - Rituxan Market (Million US$), 2016-2019
Figure 6-5: Global - Avastin Market (Million US$), 2016-2019
Figure 6-6: Global - Herceptin Market (Million US$), 2016-2019
Figure 6-7: Global - ADCETRIS Market (Million US$), 2016-2019
Figure 6-8: Global - Kadcyla Market (Million US$), 2016-2019
Figure 6-9: Global - Blincyto Market (Million US$), 2016-2019
Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2018-2024
Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Million US$), 2018-2024
Figure 6-12: Global - Provenge Market (Million US$), 2016-2019
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2018-2024
Figure 6-14: Global - Yervoy Market (Million US$), 2016-2019
Figure 6-15: Global - Opdivo Market (Million US$), 2016-2019
Figure 6-16: Global - Keytruda Market (Million US$), 2016-2019
Figure 6-17: Global - Others Immuno-oncology Drugs Market (Billion US$), 2018-2024
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2019
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2024
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2018-2024
Figure 7-4: Head & Neck Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-5: Head & Neck Cancer - Immunotherapy Clinical Studies by Phase
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2018-2024
Figure 7-7: Lung Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-8: Lung Cancer - Immunotherapy Clinical Studies by Phase
Figure 7-9: Global - Melanoma Market (Billion US$), 2018-2024
Figure 7-10: Melanoma - Immunotherapy Clinical Studies by Product-class
Figure 7-11: Melanoma - Immunotherapy Clinical Studies by Phase
Figure 7-12: Global - Lymphoma Market (Billion US$), 2018-2024
Figure 7-13: Lymphoma - Immunotherapy Clinical Studies by Product-class
Figure 7-14: Lymphoma - Immunotherapy Clinical Studies by Phase
Figure 7-15: Global - Leukemia Market (Billion US$), 2018-2024
Figure 7-16: Leukemia - Immunotherapy Clinical Studies by Product-class
Figure 7-17: Leukemia - Immunotherapy Clinical Studies by Phase
Figure 7-18: Global - Other Cancer Market (Billion US$), 2018-2024
Figure 7-19: Other Cancer - Immunotherapy Clinical Studies by Product-class
Figure 7-20: Other Cancer - Immunotherapy Clinical Studies by Phase
Figure 8-1: Global - Share of Immuno-Oncology Market by Geography (%), 2019
Figure 8-2: Global - Share of Immuno-Oncology Market by Geography (%), 2024
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2018-2024
Figure 11-1: Global - Immuno-Oncology Clinical Studies by Product-class
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2019
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2019
Figure 13-1: F. Hoffmann-La Roche AG - Revenue by Business Segment (%), 2019
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceutical Division Revenue by Geography (%), 2019
Figure 13-3: Bristol Myers Squibb - Revenue by Geography (%), 2019
Figure 13-4: Merck & Co., Inc. - Revenue by Business Segment (%), 2019
Figure 13-5: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segment (%), 2019
Figure 13-6: Merck & Co., Inc. - Revenue by Geography (%), 2019
Figure 13-7: Novartis - Revenue by Business Segment (%), 2019
Figure 13-8: Novartis - Innovative Medicines Division Revenue by Segment (%), 2019
Figure 13-9: Novartis - Pharmaceuticals Division Revenue by Segment (%), 2019
Figure 13-10: Novartis - Revenue by Geography (%), 2019
Figure 13-11: AstraZeneca Plc - Revenue by Business Segment (%), 2019
Figure 13-12: AstraZeneca Plc - Revenue by Geography (%), 2019
Figure 13-13: Pfizer Inc - Revenue by Business Segment (%), 2019
Figure 13-14: Pfizer Inc - Revenue by Geography (%), 2019
Figure 13-15: Eli Lilly and Company - Revenue by Business Segment (%), 2019
Figure 13-16: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segment (%), 2019
Figure 13-17: Eli Lilly and Company - Revenue by Geography (%), 2019
Figure 13-18: Johnson & Johnson - Revenue by Business Segment (%), 2019
Figure 13-19: Johnson & Johnson - Revenue by Pharmaceutical Segment (%), 2019
Figure 13-20: Johnson & Johnson - Revenue by Geography (%), 2019
Figure 13-21: Amgen Inc. - Revenue by Product (%), 2019
Figure 13-22: Amgen Inc. - Revenue by Geography (%), 2019
Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan
Table 6-2: Ongoing Trials for Avastin
Table 6-3: Ongoing Trials for Herceptin
Table 6-4: Ongoing Trials for ADCETRIS
Table 6-5: Ongoing Trials for Kadcyla
Table 6-6: Ongoing Trials for Blincyto
Table 6-7: Ongoing Trials for Provenge
Table 6-8: Ongoing Trials for Yervoy
Table 6-9: Ongoing Trials for Opdivo
Table 6-10: Ongoing Trials for Keytruda
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2020 & 2025
Table 9-1: Selected Immuno-Oncology and/or Targeted Therapy Combinations
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
Table 11-1: Global - Immuno-Oncology Product Pipeline
Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2017-2019
Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
Table 13-4: Bristol Myers Squibb - Key Financials (Billion US$), 2017-2019
Table 13-5: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
Table 13-6: Bristol Myers Squibb - Product Pipeline
Table 13-7: Merck & Co., Inc. - Key Financials (Billion US$), 2017-2019
Table 13-8: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
Table 13-9: Merck & Co., Inc. - Product Pipeline
Table 13-10: Novartis - Key Financials (Billion US$), 2017-2019
Table 13-11: Novartis - Commercialized Immuno-Oncology Products
Table 13-12: Novartis - Product Pipeline
Table 13-13: AstraZeneca Plc - Key Financials (Billion US$), 2017-2019
Table 13-14: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-15: AstraZeneca Plc - Product Pipeline
Table 13-16: Pfizer Inc - Key Financials (Billion US$), 2017-2019
Table 13-17: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-18: Pfizer Inc - Product Pipeline
Table 13-19: Eli Lilly and Company - Key Financials (Billion US$), 2017-2019
Table 13-20: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-21: Eli Lilly and Company - Product Pipeline
Table 13-22: Johnson & Johnson - Key Financials (Billion US$), 2017-2019
Table 13-23: Johnson & Johnson - Commercialized Immuno-Oncology Products
Table 13-24: Johnson & Johnson - Product Pipeline
Table 13-25: Amgen Inc. - Key Financials (Billion US$), 2017-2019
Table 13-26: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-27: Amgen Inc. - Product Pipeline
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact